Spironolactone Pre-Surgery Hold Window: What Clinicians and Patients Need to Know
At a glance
- Surgery-related label use / short-term preoperative treatment of primary hyperaldosteronism, 100 to 400 mg daily [1]
- Spironolactone half-life / about 1.4 hours [1]
- Active metabolite half-lives / canrenone 16.5 h, TMS 13.8 h, HTMS 15 h [1]
- Label monitoring rule / potassium within 1 week of starting or titrating, then regularly [1]
- Drugs that add potassium risk / ACE inhibitors, ARBs, potassium supplements, salt substitutes, NSAIDs, heparin, trimethoprim [1]
- Acne regimen in the SAFA trial / 50 mg daily for 6 weeks, then 100 mg daily to week 24 [2]
What the label says about surgery
The Aldactone label lists short-term preoperative treatment of primary hyperaldosteronism, at 100 to 400 mg daily in preparation for surgery [1]. For other uses it describes monitoring and dose limits. Hyperkalemia is a contraindication, and if it occurs the label says to decrease the dose or discontinue and treat [1].
How long does spironolactone stay active?
Spironolactone has a mean half-life of about 1.4 hours and peaks at 2.6 hours [1]. Its metabolites last longer: canrenone 16.5 hours, TMS 13.8 hours and HTMS 15 hours, with canrenone peaking at 4.3 hours [1]. The label does not translate these figures into a pre-surgery stop interval.
Which patients carry the highest potassium risk?
The label names impaired renal function, potassium supplements, potassium-containing salt substitutes, and potassium-raising drugs such as ACE inhibitors and angiotensin receptor blockers [1]. NSAIDs, heparin and low molecular weight heparin, and trimethoprim are also listed [1]. The label says to check serum potassium within a week of starting or titrating and regularly after that, with more frequent monitoring when other potassium-raising drugs are given or kidney function is impaired [1].
The label also warns that excessive diuresis may cause dehydration, hypotension and worsening renal function, particularly in salt-depleted patients or those taking ACE inhibitors or angiotensin II receptor blockers. It says NSAIDs, aminoglycosides and cisplatin can add to the risk of worsening renal function [1].
Acne doses and healthy patients
Acne is not a labeled use [1]. In the SAFA trial, 410 women with persistent facial acne took 50 mg daily for 6 weeks, then 100 mg daily to week 24, alongside usual topical treatment [2]. In a retrospective study of 974 healthy young women taking spironolactone for acne, 13 of 1,802 potassium measurements were abnormal (0.72%), compared with a 0.76% baseline rate in 1,165 comparison women. Six of the 13 abnormal values were normal on repeat [3]. That study excluded people with heart or kidney disease and those taking drugs that affect the renin-angiotensin system [3]. The Aldactone label itself still says to monitor potassium [1].
What matters on the day of a procedure
The label's warnings make a current potassium value and a complete medication and supplement list relevant, including potassium supplements, potassium-containing salt substitutes, ACE inhibitors, ARBs, NSAIDs, heparin and trimethoprim [1]. A general review of perioperative medication management says decisions about stopping or continuing a drug should weigh withdrawal potential, the risk of disease progression if treatment is interrupted, possible interactions with anesthesia, and short-term quality of life [4]. That review is not specific to spironolactone.
Frequently asked questions
How many days before surgery should spironolactone be stopped?
Does the label recommend a potassium check before a procedure?
Do lower acne doses change the risk?
How long does spironolactone stay in the body?
References
- U.S. National Library of Medicine, DailyMed. Aldactone (spironolactone) tablets, Pfizer prescribing information. Aldactone (spironolactone) tablets, Pfizer label
- Santer M, Lawrence M, Pyne S, Renz S, Stuart BL, Sach T, et al. Clinical and cost-effectiveness of spironolactone in treating persistent facial acne in women: SAFA double-blinded RCT. Health Technol Assess. 2024. Clinical and cost-effectiveness of spironolactone in treating persistent facial acne in women: SAFA double-blinded RCT
- Plovanich M, Weng QY, Mostaghimi A. Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne. JAMA Dermatol. 2015;151(9):941-4. Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne
- Whinney C. Perioperative medication management: general principles and practical applications. Cleve Clin J Med. 2009;76 Suppl 4:S126-32. Perioperative medication management: general principles and practical applications